Resumen de Investigación
Analyzed using Evidence Intelligence™

Intensive glycemic control may lower cardiovascular events in some diabetes patients

Powered by the Dediabetes Evidence Intelligence™ framework

Última actualización 6 de julio de 2026

Key finding

Intensive glycemic control was associated with lower MACE in pooled study data.

This study examined the effects of intensive versus standard glycemic control on cardiovascular events in type 2 diabetes patients, finding no significant differences in certain outcomes.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Extended (5–20+ y)

Risk of bias

Some Concerns

Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.

Plain-language summary

What this paper says

A plain-language read of the study's main message and where it applies.

Study focus

This study examined the effects of intensive versus standard glycemic control on cardiovascular events in type 2 diabetes patients, finding no significant differences in certain outcomes.

Clinical relevance

Understanding the varying effects of glycemic control on cardiovascular outcomes is crucial for tailoring diabetes management strategies. This study highlights the need for personalized treatment approaches, as intensive glycemic control may not benefit all patients equally, potentially guiding clinicians in making informed decisions about diabetes care.

Keep in mind

Effectiveness of interventions was unclear in some cases. Results may not be generalizable to all populations. Subgroup analyses had varying outcomes, complicating interpretations.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Justin AE, Kevin J, Gideon B, et al. Heterogeneous Treatment Effects of Intensive Glycemic Control on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients. Cardiovascular Diabetology. 2022;21:58. doi:10.1186/s12933-022-01496-7

View DOIView on PubMedView on PMC

Efectos Principales

Intensive glycemic control was associated with a 4.2% decrease in composite cardiovascular events in pooled data.

No significant difference in composite cardiovascular events was noted in some subgroups.

All-cause mortality rates showed no significant difference between the two treatment groups.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Intensive glycemic control, Standard glycemic control and All-cause mortality, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).

This study contributes evidence to

Intervention

Intensive glycemic control

Outcome

All-cause mortality

Evidence topic

Cardiovascular Risk

Primary intervention

Intensive glycemic control

Primary outcomes

  • All-cause mortality
  • Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence topics

Cardiovascular Risk

Primary intervention

Intensive glycemic control

Primary outcomes

All-cause mortalityComposite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

3
Evidence pairs
3
Relationships
1
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 59

1

Related topics

3

Evidence pairs

39

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 3 evidence relationships
  • Includes primary outcome data
  • Linked to 1 direct semantic evidence topic

Topic contributions

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Relación de evidencia

Glycemic Control Treatments and Cardiovascular Outcomes

Evidencia relacionada

Tema de evidencia

Cardiovascular Risk

Seguir evidencia

Intervención

Glycemic Control Treatments

Seguir intervención

Core evidence

Study findings

The primary outcomes reported in this study.

All-cause mortality

Intensive glycemic control → All-cause mortality

Intensive glycemic control → All-cause mortality

Evidence Intelligence™
ImpactScore™
50
Neutral
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Standard glycemic control → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Standard glycemic control → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence Intelligence™
ImpactScore™
50
Neutral
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Build your personal Evidence Workspace

Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Today's Activity

Your Evidence Workspace

Free account

Saved this study

Your free account becomes your personal diabetes evidence workspace.

Evidence Tracker

12 tracked topics

Saved Studies

48 studies

Research Notes

Coming Soon

Weekly Evidence Digest

Coming Soon

evidence suggest

La Evidencia Sugiere

  • Intensive glycemic control reduced MACE by 4.2% in pooled data.
  • No significant differences in MACE were found in certain subgroups.
  • All-cause mortality rates were similar between treatment groups.
who this applies

A quién se aplica

  • Adults diagnosed with type 2 diabetes.
  • Patients undergoing glycemic control treatment.
keep in mind

Tener en Cuenta

  • The study's findings may not apply to all diabetes patients.
  • Subgroup differences highlight the need for personalized treatment.
  • Unclear effectiveness suggests further research is needed.
between the lines

Entre Líneas

  • Effectiveness of interventions was unclear in some cases.
  • Results may not be generalizable to all populations.
  • Subgroup analyses had varying outcomes, complicating interpretations.

Save this study

Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.

Today's Activity

Your Evidence Workspace

Free account

Saved this study

Your free account becomes your personal diabetes evidence workspace.

Evidence Tracker

12 tracked topics

Saved Studies

48 studies

Research Notes

Coming Soon

Weekly Evidence Digest

Coming Soon

Already have an account?

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Powered by the Dediabetes Evidence Intelligence™ framework

This study contributes to evidence on Glycemic Control Treatments and Cardiovascular Outcomes, Glycemic Control Treatments and Cardiovascular Outcomes.

Relaciones de evidencia relacionadas

Explore in Evidence Archive

This study contributes to the evidence on the following intervention-outcome relationships.

Explora más en el archivo de evidencia

Jump to pre-filtered views in the evidence archive.

All studies on Intensive glycemic control and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Intervention: Intensive glycemic controlOutcome: Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

2 results

All studies on Intensive glycemic control and All-cause mortality

Intervention: Intensive glycemic controlOutcome: All-cause mortality

1 results

All studies on Intensive glycemic control

Intervention: Intensive glycemic control

2 results

All studies measuring Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Outcome: Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

2 results

All studies measuring All-cause mortality

Outcome: All-cause mortality

1 results

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Glycemic Control Treatments improve cardiovascular outcomes?

Strong Evidence

Glycemic Control Treatments may improve Cardiovascular Outcomes.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: The available evidence reports mixed findings.

Ranked evidence signals

  1. 1

    Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 1 study

  2. 2

    All-cause mortality

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Population details are unavailable.
3 supporting studiesUpdated: Jul 2026
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, archive views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Cardiovascular Risk Evidence Hub

Explore in archive

Open broader archive views for this relationship.

All studies on Intensive glycemic control and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)All studies on Intensive glycemic control and All-cause mortalityAll studies on Standard glycemic control and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Related research

Read related research summaries.

IGF-1 levels may predict type 2 diabetes in ACS patientsCanagliflozin reduces cardiovascular and kidney risks in type 2 diabetesCanagliflozin with metformin reduces cardiovascular risk in T2DMHbA1c mediates cardiovascular benefits of GLP-1 receptor agonistsIntensive multifactorial therapy reduces mortality risk in women with diabetes

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.